This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Graphical Abstract
Highlights
BRD4 interaction with prolyl hydroxylase domain proteins.
Stoichiometric dynamics and site-specific regulation of BRD4 proline hydroxylation.
BRD4 interactome analysis in response to prolyl hydroxylase activity.
Proline hydroxylation pathway regulation of BRD4-mediated transcriptional activity.
Abstract
Proline hydroxylation is a critical cellular mechanism regulating energy homeostasis and development. Our previous study identified and validated Bromodomain-containing protein 4 (BRD4) as a proline hydroxylation substrate in cancer cells. Yet, the regulatory mechanism and the functional significance of the modification remain unknown. In this study, we developed targeted quantification assays using parallel-reaction monitoring and biochemical analysis to identify the major regulatory enzyme of BRD4 proline hydroxylation. We further performed quantitative interactome analysis to determine the functional significance of the modification pathway in BRD4-mediated protein-protein interactions and gene transcription. Our findings revealed that PHD2 is the key regulatory enzyme of BRD4 proline hydroxylation and the modification significantly affects BRD4 interactions with key transcription factors as well as BRD4-mediated transcriptional activation. Taken together, this study provided mechanistic insights into the oxygen-dependent modification of BRD4 and revealed new roles of the pathway in regulating BRD4-dependent gene expression.
- Omics
- Affinity proteomics
- Label-free quantification
- Post-translational modifications*
- Transcription*
- BRD4
- oxygen sensing
- PHD2
- proline hydroxylation
Footnotes
Author contributions: L.N.E. and A.L. performed research; L.N.E. and A.L. analyzed data; L.N.E. and Y.C. wrote the paper; Y.C. designed research.
↵* This work was supported by the University of Minnesota research start-up fund (to Y.C.) and the National Institute of Health (1R35GM124896 to Y.C.).
↵
This article contains supplemental material.
- Received April 30, 2019.
- Revision received June 19, 2019.
- © 2019 Erber et al.
Published under exclusive license by The American Society for Biochemistry and Molecular Biology, Inc.